Biopharmaceutical research has never been for the faint of heart. For small biotech companies working on the absolute edge of innovation, one clinical trial can literally mean the difference between closing up shop or commercializing a breakthrough, life-saving medicine. And even for big pharmaceutical companies, setbacks have always been inevitable – the nature of discovery means that success comes only after years of trial and error.
How can we detect ovarian cancer before it’s too late? Can we make wounds heal faster? What are the alternatives to bariatric surgery for people with type 2 diabetes? Is there a way to reduce complications and cost in reconstructive surgery?
The University of Maryland, Baltimore (UMB) held a grand opening for its Community Engagement Center in West Baltimore at 1 N. Poppleton St. on Saturday, April 16, including a spring community festival to introduce the neighborhood to the center and its valuable services. Maryland’s First Lady Yumi Hogan was a guest at the grand opening, assisted with the ribbon-cutting, and spent the day with community members at the spring festival.
Baltimore is in line to have two schools that offer a career pathway program developed by IBM.
Gov. Larry Hogan signed a bill into law on Tuesday that provides framework and funding for P-TECH in the state. The Pathways in Technology Early College High School program follows a model of partnering with companies to provide students with STEM skills so they are immediately ready for a job. Starting the program in 9th grade, the students receive a high school diploma, associate’s degree and additional workforce training.
Emergent BioSolutions has filed a supplemental Biologics License Application with the U.S. Food and Drug Administration to scale up production of its anthrax vaccine BioThrax. BioThrax is the only FDA-approved anthrax vaccine for humans. It’s primarily produced for and purchased by the U.S. military, and has been in distribution since the 1970s.
If academic discoveries turn out to be wrong, one drug company wants its money back.
That’s the tough-minded proposal floated today by the chief medical officer of Merck & Co., one of the world’s 10 largest drug companies, as a way to fix the “reproducibility crisis,” or how many, if not most, published scientific reports turn out to be incorrect.
May 8-11, 2016 – Grand Hyatt Washington DC in Washington, DC
Health Datapalooza is the gathering place for people and organizations creating knowledge from data and pioneering innovations that drive health policy and practice, and generate market value. Conceived as part of a public/private movement to liberate and use health data, the Datapalooza continues its tradition of engaging patient and consumer voices, and bringing national and international leaders from the C-levels of business and government together for engaging discussions.
We’re excited to invite you to join us for the 2016 Health Datapalooza – the meeting that brings data to life in ways that matter in health and health care. This year’s meeting finds us even closer to the reality of using data, analytics, and technology to re-define how we deliver and pay for health care. Come hear how data sharing, use, and transparency fuels innovative applications and business models that are building momentum towards a vibrant health information economy that drives high value health care.
Presented by the Tech Council of Maryland, Bio+Tech16 reflects the changing landscape where life sciences and technology converge by bringing together more than 500 professionals in both fields so that they may meet and forge new partnerships that will lead to great new discoveries. Bio+Tech16 is the first event of its kind in the Mid-Atlantic region that brings together the life science and technology sectors to meet and leverage the talents of the other to grow their organizations and their industry.
A simple blood test to detect early signs of cancer. A noninvasive way to screen pregnancies for common genetic conditions. An app store for your genetic information. Illumina, a San Diego-based gene-sequencing hardware and software behemoth with a market capitalization of $22 billion, is working on all these initiatives—and more.
University tech transfer offices play a central role in the biotech ecosystem, as the successful commercialization of an academic discovery is the aspiration of many young startups. Navigating–and optimizing–this tech transfer process is therefore critical to the health of the biotech sector.
